Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis.
about
Role of NLRP3 Inflammasome in the Progression of NAFLD to NASHPromising Therapy Candidates for Liver FibrosisNonalcoholic fatty liver disease: new treatmentsInfiltrating monocytes in liver injury and repairHow Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future DirectionsTargeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic SteatohepatitisPromising therapies for treatment of nonalcoholic steatohepatitis.T2 relaxation time is related to liver fibrosis severity.Mechanisms of Liver Injury in Non-Alcoholic SteatohepatitisA positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitisBoth bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis.Mechanism of the promotion of steatotic HepG2 cell apoptosis by cholesterolFocus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis.Death receptor 5 signaling promotes hepatocyte lipoapoptosisInhibition of apoptosis protects mice from ethanol-mediated acceleration of early markers of CCl4 -induced fibrosis but not steatosis or inflammation.Cell death and cell death responses in liver disease: mechanisms and clinical relevanceAlcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles.Inhibition of apoptosis in the management of nonalcoholic fatty liver disease.Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injuryA phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis.Lipid metabolism, oxidative stress and cell death are regulated by PKC delta in a dietary model of nonalcoholic steatohepatitis.Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications.Mitochondrial dysfunction in nonalcoholic steatohepatitis.The epidemiology, pathogenesis and histopathology of fatty liver disease.Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects?Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.The genetics of NAFLD.Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.Current and prospective pharmacotherapy for autoimmune hepatitis.Targeting apoptosis in autoimmune hepatitis.Strategies to prevent and reverse liver fibrosis in humans and laboratory animals.Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes.Quantifying hepatic steatosis - more than meets the eye.Mechanisms of the prevention and inhibition of the progression and development of non-alcoholic steatohepatitis by genetic and pharmacological decoy receptor 3 supplementation.
P2860
Q26742102-9A0B1799-14E1-4A00-83BD-F0C223B22B4FQ26766727-C60049AC-89D8-492A-AF61-4CC919A6DB11Q27021161-81B864F6-AFD5-43EF-9033-0BA1C516066BQ28070341-21AFC840-E119-4A6E-8C0A-B4FB612F82E2Q28074455-9DCA054F-3B7D-46CE-A012-CFB09E68ACAFQ28076505-2B32FF75-C760-46BB-BB9D-3E0F257619B6Q28077079-649F6CB9-BD08-4FB4-AECA-CA3D3A9B9B82Q30248578-23A8A37F-87EA-435C-B9AD-85612C05FC74Q30383680-86A29BD3-23FB-49D5-8A6A-186D96AB1733Q33898945-EF30B639-61C1-4DF5-9BBF-0DD5D69822ABQ34131187-FF28A44F-31A0-4D86-8116-BA73570406E8Q34214279-1EF06611-990B-4343-8527-960D6B0DE27BQ34501819-DD91257B-C2A8-4404-B644-BD3D73610A2CQ34647400-0A30EC01-A43F-43D0-B911-139E814FA858Q35122049-017FA3A4-8812-4602-9FC2-D28359F9A37CQ35604362-FE7E40C4-E3BE-4A5E-A7CF-84469DAB06AEQ35916623-E77CFBCB-FFF0-42E4-8A99-C96E20C8CE0DQ35938040-2F6EFAFD-E247-4327-9316-F8A963B787FBQ36600231-B5324C68-6795-4C5D-84E8-0EFA4F66185EQ36693152-AFA4B610-2D8E-4AF4-A6AE-7E983FA7F31AQ36774034-A99179A3-B82D-4753-BD9D-E93A77EE4D0EQ37189403-BB6D45ED-7E3F-43C8-BF40-1303A9E3DDC2Q37484376-A2E956B8-4929-485F-A768-2523C5CDDC05Q37708036-7AD9784B-6920-4C1D-A40F-A030C96D8D52Q37863133-A677EE0E-04FB-45C6-BA91-D6D9C5E52EB7Q37863137-A7A0F958-92CD-4F78-A646-4039B0C7AE49Q37988893-60092605-B453-49BD-BFED-2DC82CA9ED83Q38066240-C47A5A7A-AFDD-4983-96CB-E66C5263C673Q38121574-AFADCD5B-1F35-4303-B702-F496012E8AF7Q38128548-00528D14-29F7-4BDB-AF6B-C41C80407BA9Q38141714-DF186012-38F4-4CEE-9F23-31203F3D8889Q38204970-C5CC8E60-8CDF-450B-87D1-E5B507327299Q38222882-B0247008-4476-4E80-8F08-94EE011DE511Q38231217-B052E017-9331-4036-9506-DACD949564E2Q38473640-048691D8-05D1-4E3B-BD9F-0D68FBFF629DQ38496935-32472F28-943B-4B5B-9F51-963FADEDC744Q38802973-325D9358-741A-489B-B10E-73DA4D72B0FCQ38803828-D76E4D85-7F57-4623-81D9-A28FC5BA80C6Q40023832-148A74AA-5975-4B0C-80BF-04CA64FE9EDEQ40380042-67DC8558-BD26-4630-84C0-CBB04AB592F2
P2860
Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Impact of pan-caspase inhibiti ...... non-alcoholic steatohepatitis.
@en
Impact of pan-caspase inhibiti ...... non-alcoholic steatohepatitis.
@nl
type
label
Impact of pan-caspase inhibiti ...... non-alcoholic steatohepatitis.
@en
Impact of pan-caspase inhibiti ...... non-alcoholic steatohepatitis.
@nl
prefLabel
Impact of pan-caspase inhibiti ...... non-alcoholic steatohepatitis.
@en
Impact of pan-caspase inhibiti ...... non-alcoholic steatohepatitis.
@nl
P2093
P1476
Impact of pan-caspase inhibiti ...... non-alcoholic steatohepatitis
@en
P2093
Adam Levene
Danilo Concas
Howard C Thomas
John Pollard
Mark R Thursz
Peter Charlton
Robert D Goldin
P304
P356
10.1016/J.JHEP.2010.03.016
P577
2010-05-26T00:00:00Z